Serial Number
98432118
Owner
Mirador Therapeutics, Inc.Attorney
Brent D. SokolFiling Date
Mar 4, 2024
MIRADOR360 Trademark
Serial Number: 98432118
Trademark Classes
Owner Contact Info
3115 Merryfield Row, Suite 210
San Diego, CA 92121
Entity Type: 03
Legal Representation
Correspondence Address
Brent D. Sokol Greenberg Traurig, LLP
1840 Century Park East, Suite 1900
Los Angeles, CA 90067
United States
Trademark Details
Filing Date
March 4, 2024
Registration Date
Not Registered
Published for Opposition
February 25, 2025
Goods & Services
Scientific research services in the nature of collecting and analyzing patient data and genetic information for pharmaceutical drug development and diagnostics development including companion diagnostics development and complementary diagnostics development; Scientific research services in the nature of collecting and analyzing patient data including genetic information for selecting and validating therapeutic targets for pharmaceutical development as well as for predicting, measuring or evaluating the performance of therapeutic molecules directed at therapeutic targets; Scientific research services in the nature of collecting and analyzing patient data including genetic information for selecting and validating biomarkers and other criteria for diagnostics including companion diagnostics development and complementary diagnostics development as well as for predicting, measuring or evaluating the performance of the diagnostics; Scientific research services in the nature of collecting and analyzing patient data including genetic information for selecting and validating biomarkers and other criteria for selecting patients for inclusion in clinical treatment including clinical trials as well as for predicting, measuring or evaluating the performance of the patient selecting criteria; Scientific research services in the nature of collecting patient data and genetic information and analysis of such data for identifying and recruiting patients for participation in clinical trials for pharmaceutical drug development, matching patients with clinical trials and for measuring and monitoring the performance of clinical trials for pharmaceutical drug development; providing a platform as a service featuring a computer software platform for selecting, validating and evaluating therapeutic targets and therapeutic molecules in the field of pharmaceutical development; providing a platform as a service featuring a computer software platform for selecting, validating and evaluating biomarkers and other patient-selecting or patient-identifying criteria in the field of diagnostic development including companion diagnostics development and complementary diagnostics development